Having observed that the inhibition of SRC/FAK signaling in H358-S and other NSCLC cells leads to decreased invasive ability, we sought to study the effects of these inhibitors on erlotinib sensitivity of smoke-exposed cells. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.